Sveikuva

JSC SVEIKUVA is providing regulatory affairs and pharmacovigilance services related to obtaining and maintaining of medicines marketing authorization in Baltic States (Lithuania, Latvia and Estonia) since the year 2003.

Our aim

To work timely, reliably and advisedly, in order our clients could achieve their plans.

If You are looking for solution, advice us...

Human medicines European Public Assessment Report (EPAR): Prolia, denosumab, Revision: 2, Authorised
Human medicines European Public Assessment Report (EPAR): Fablyn, lasofoxifene, Revision: 2, Authorised
Human medicines European Public Assessment Report (EPAR): Circadin, melatonin, Revision: 14, Authorised
Human medicines European Public Assessment Report (EPAR): Prometax, rivastigmine, Revision: 23, Authorised
Human medicines European Public Assessment Report (EPAR): Prometax, rivastigmine, Revision: 23, Authorised

Professionalism.
We are specialists in this field and like our activity, so we can guarantee the quality of our work.
Competitiveness.
Individual solutions for a competitive price.
Confidentiality.
We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership

Member of Medicines Manufacturers Association